Quantification of [ 18F]diprenorphine kinetics in the human brain with compartmental and non-compartmental modeling approaches

NeuroImage

Volumn 22, Issue 4, 2004, Pages 1523-1533

  Spilker, Mary E ^a   Sprenger, Till ^a   Valet, Michael ^a   Henriksen, Gjermund ^a   Wagner, Klaus ^a   Wester, Hans J ^a   Toelle, Thomas R ^a   Boecker, Henning ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

1T; 2T; 18F diprenorphine; basis function method; BFN; binding potential; BP; distribution volume; DV; Inv_Logan; invasive Logan model; Kinetic models; Ligand; one tissue compartmental model; Opiate receptors; PET; two tissue compartmental model

Indexed keywords

DIPRENORPHINE F 18; OPIATE RECEPTOR; TRACER; UNCLASSIFIED DRUG; DIPRENORPHINE; FLUORINE;

ADULT; ARTICLE; BRAIN REGION; BRAIN SCINTISCANNING; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; KINETICS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOBIOLOGY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION; BIOLOGICAL MODEL; BRAIN; BRAIN CORTEX; CEREBELLUM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEMISPHERIC DOMINANCE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SCINTISCANNING; THALAMUS;

ADULT; BRAIN; CEREBELLUM; CEREBRAL CORTEX; DIPRENORPHINE; DOMINANCE, CEREBRAL; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; KINETICS; MALE; MIDDLE AGED; MODELS, NEUROLOGICAL; RECEPTORS, OPIOID; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 3242685420     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2004.04.009     Document Type: Article

References (30)

1. Akaike H. A new look at the statistical model identification. IEEE Trans. Autom. Control. 19:1974;716-723
2. Alpert N.M., Badgaiyan R.D., Livni E., Fischman A.J. A novel method for noninvasive detection of neuromodulatory changes in specific neurotransmitter systems. NeuroImage. 19(3):2003;1049-1060. (Jul.)
3. 11C]diprenorphine studies. J. Cereb. Blood Flow Metab. 23(S1):2003;679. (Jun.)
4. 18F]cyclofoxy and positron emission tomography. J. Cereb. Blood Flow Metab. 13(1):1993;24-42. (Jan.)
5. Duncan J.S. Positron emission tomography receptor studies in epilepsy. Rev. Neurol. (Paris). 155(6-7):1999;482-488. (Review, Jul.)
6. 11C]carfentanil: reference-tissue methods. Nucl. Med. Biol. 30(2):2003;177-186. (Feb.)
7. 11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J. Cereb. Blood Flow Metab. 9(3):1989;398-409. (Jun.)
8. Gunn R.N., Gunn S.R., Cunningham V.J. Positron emission tomography compartmental models. J. Cereb. Blood Flow Metab. 21(6):2001;635-652. (Jun.)
9. Gunn R.N., Gunn S.R., Turkheimer F.E., Aston J.A., Cunningham V.J. Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J. Cereb. Blood Flow Metab. 22(12):2002;1425-1439. (Dec.)
10. Jones A.K., Liyi Q., Cunningham V.V., Brown D.W., Ha-Kawa S., Fujiwara T., Friston K.F., Silva S., Luthra S.K., Jones T. Endogenous opiate response to pain in rheumatoid arthritis and cortical and subcortical response to pain in normal volunteers using positron emission tomography. Int. J. Clin. Pharmacol. Res. 11(6):1991;261-266
11. 11C] diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols. J. Neurosci. Methods. 51(2):1994;123-134. (Mar.)
12. Lammertsma A.A. Radioligand studies: imaging and quantitative analysis. Eur. Neuropsychopharmacol. 12(6):2002;513-516. (Dec.)
13. Lammertsma A.A., Hume S.P. Simplified reference tissue model for PET receptor studies. NeuroImage. 4(3 Pt 1):1996;153-158. (Dec.)
14. Laruelle M., Slifstein M., Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods. 27(3):2002;287-299. (Jul.)
15. 18F]Fluor-Ethyl-Diprenorphine. J. Cereb. Blood Flow Metab. 23(S1):2003;669. (Jun.)
16. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl. Med. Biol. 27(7):2000;661-670. (Oct.)
17. Mayberg H.S., Sadzot B., Meltzer C.C., Fisher R.S., Lesser R.P., Dannals R.F., Lever J.R., Wilson A.A., Ravert H.T., Wagner H.N. Jr., Bryan N., Cromwell C.C., Frost J.J. Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography. Ann. Neurol. 30(1):1991;3-11. (Jul.)
18. Meyer J.H., Ichise M. Modeling of receptor ligand data in PET and SPECT imaging: a review of major approaches. J. Neuroimaging. 11(1):2001;30-39. (Jan.)
19. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 15(3):1984;217-227. (Mar.)
20. Pappata S., Dehaene S., Poline J.B., Gregoire M.C., Jobert A., Delforge J., Frouin V., Bottlaender M., Dolle F., Di Giamberardino L., Syrota A. In vivo detection of striatal dopamine release during reward: a PET study with [(11)C]raclopride and a single dynamic scan approach. NeuroImage. 16(4):2002;1015-1027. (Aug.)
21. Pfeiffer A., Pasi A., Mehraein P., Herz A. Opiate receptor binding sites in human brain. Brain Res. 248(1):1982;87-96. (Sep. 23)
22. Piccini P., Weeks R.A., Brooks D.J. Alterations in opioid receptor binding in Parkinson's Disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42:1997;720-726
23. Sadzot B., Mayberg H.S., Frost J.J. Imaging opiate receptors in the human brain with positron emission tomography. Potential applications for drug addiction research. Acta Psychiatr. Belg. 90(1):1990;9-19. (Jan-Feb.)
24. Slifstein M., Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J. Nucl. Med. 41(12):2000;2083-2088. (Dec.)
25. Slifstein M., Laruelle M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl. Med. Biol. 28(5):2001;595-608. (Jul.)
26. 18F]-diprenorphine displacement in the limbic system. J. Cereb. Blood Flow Metab. 23(S1):2003;719. (Jun.)
27. Weeks R.A., Cunningham V.J., Piccini P., Waters S., Harding A.E., Brooks D.J. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J. Cereb. Blood Flow Metab. 17(9):1997;943-949. (Sep.)
28. Wester H.J., Willoch F., Tolle T.R., Munz F., Herz M., Oye I., Schadrack J., Schwaiger M., Bartenstein P. 6-O-(2-[18F]fluoroethyl)-6-O- desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. J. Nucl. Med. 41(7):2000;1279-1286. (Jul.)
29. Willoch F., Tölle T.R., Wester H.J., Munz F., Petzold A., Schwaiger M., Conrad B., Bartenstein P. Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. AJNR Am. J. Neuroradiol. 20(4):1999;686-690. (Apr.)
30. Willoch F., Schindler F., Wester H.J., Empl M., Straube A., Schwaiger M., Conrad B., Tölle T.R. Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a 11C-diprenorphine PET study. Pain. 108:2004;213-220. (Apr.)